Von Willebrand disease - management
VWD mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
The commonest inherited bleeding disorder, from quantitative or qualitative deficiency of von Willebrand factor. Management is tailored to type and bleeding risk, using desmopressin, antifibrinolytics and VWF-containing concentrates around challenges.
Red flags
- Life-threatening or intracranial bleeding
- Type 2B with desmopressin-induced thrombocytopenia
- Severe menorrhagia with anaemia
- Major surgery without a factor plan
- Postpartum haemorrhage
Assessment
Differential diagnosis
- Platelet function disorder
- Haemophilia A (mild)
- Acquired von Willebrand syndrome
- Connective tissue / vascular bleeding
- Thrombocytopenia
Investigations
- FBC and coagulation screen (APTT may be prolonged)
- VWF antigen and VWF activity (ristocetin cofactor / GPIbM assay)
- Factor VIII level
- VWF multimer analysis to subtype
- Blood group (type O lowers baseline VWF)
- Desmopressin trial response where relevant
Management
- Confirm diagnosis and subtype (type 1 partial quantitative, type 2 qualitative variants, type 3 severe quantitative)
- Assess bleeding phenotype and planned procedures/pregnancy
- Establish an individualised treatment plan with a haemophilia centre
- For minor bleeding/mucosal bleeding use tranexamic acid
- Use desmopressin for type 1 and responsive type 2 (releases endogenous VWF) after a documented trial - avoid in type 2B and type 3
- Give VWF/FVIII concentrate for major bleeding, surgery, type 3, or desmopressin non-responders
- Combine antifibrinolytics with other measures for mucosal/dental bleeding
- Manage menorrhagia with tranexamic acid, hormonal therapy, and VWF cover as needed
- Plan pregnancy and delivery with factor monitoring (VWF rises in pregnancy but falls postpartum)
- Avoid NSAIDs and antiplatelets; provide a treatment card and genetic counselling
Drugs & doses
Tranexamic acid 1 g PO/IV three times daily (or 15-25 mg/kg)
Desmopressin 0.3 mcg/kg IV/SC (or 300 mcg intranasal) with fluid restriction
VWF/FVIII concentrate dosed to target VWF:RCo / FVIII per procedure
Recombinant VWF (vonicog alfa) per protocol for major bleeding
Disposition
Haemophilia/comprehensive care centre; outpatient management with procedure-specific planning; admit for major bleeds.
Complications & pitfalls
- Iron deficiency from chronic mucosal/menstrual loss
- Hyponatraemia from repeated desmopressin
- Bleeding with inadequate perioperative cover
- Alloantibodies in type 3
- Postpartum haemorrhage
Exam pearls
- Always document a desmopressin trial response before relying on it
- Desmopressin is contraindicated in type 2B (worsens thrombocytopenia) and ineffective in type 3
- Tranexamic acid is highly effective for mucosal and menstrual bleeding
- VWF levels rise in pregnancy but drop sharply after delivery - cover the postpartum period
- Avoid NSAIDs and aspirin
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.